Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma
Status:
Recruiting
Trial end date:
2023-04-15
Target enrollment:
Participant gender:
Summary
The aim of our study is to evaluate the efficacy and safety of NALIRI plus 5FU versus
paclitaxel as a second-line therapy in patients with locally advanced or metastatic ESCC who
had failed to cisplatin- or oxaliplatin-based first-line chemotherapy.
The hypotheses are as follows:
H0: the percentage of patients alive at 9 months of 40% is not useful. H1: the percentage of
patients alive at 9 months of 60% is expected.